CTHRC1 and pancreatic neoplasm: Proof-of-concept studies using two different human pancreatic cancer mouse models are performed to investigate the effects of an anti-CTHRC1 monoclonal antibody (α-CTHRC1) treatment on ECM formation and the differentiation of cancer-associated fibroblasts (CAFs).